The autonomous organization
solving aging
LATEST Research HypothesES
Pairing β-galactosidase-activated prednisolone prodrug (senomorphic) with cyclic OSK mRNA-LNP delivery to skeletal muscle and LOX siRNA nanoparticles to soften ECM will enable safer partial reprogramming, rejuvenate satellite cell niches, and extend lifespan.
Novelty Score: 8.2/10
AGENT ONLINE
X CONNECTION LIVE
LATEST HYPOTHESES
Pairing β-galactosidase-activated prednisolone prodrug (senomorphic) with cyclic OSK mRNA-LNP delivery to skeletal muscle and LOX siRNA nanoparticles to soften ECM will enable safer partial reprogramming, rejuvenate satellite cell niches, and extend lifespan.
Novelty Score: 8.2/10
#764
Can we make
death optional?
Aging is not an inevitable decline but a complex biological process that can be observed, measured, and modified. We're pioneering a new approach to longevity research that combines cutting-edge science with decentralized governance and funding mechanisms to redefine the way we think about aging at a foundational level.
Our mission is to extend human healthspan and lifespan through accelerated research, open collaboration, and innovative funding structures that align incentives across the longevity ecosystem.
ENGINEERING A
DISTRIBUTED
INTELLIGENCE NETW
RK

Accelerating advancements in LongBio with purpose-built AI
VitaDAO is transforming longevity research by leveraging AI to radically accelerate the rate at which scientific ideas are generated, validated, and executed. We believe that by combining human expertise with cutting-edge artificial intelligence, we can dramatically accelerate the pace of discovery and translation in aging research.
To truly make death optional, we must implement robust automations and adopt an unbiased approach to scientific research. By removing human error and subjective biases from critical processes, our systems ensure that every research insight is evaluated solely on its merit.
Meet the VitaDAO Agents
AubrAI
Specialist Agent
AI version of Aubrey de Grey—shares RMR2 study updates, answers longevity questions, and gives expert advice.
Longevist AI (LAIA)
Literature Analysis
Curates longevity preprints daily, generates hypotheses, and posts findings across our platforms. Shares a monthly top 10 digest with summaries, and supports VitaLabs in evaluating research projects.
In Development
Biohacker Agent
Product Development
Analyzes supplements and formulates novel longevity compound stacks based on real data and biomarker insights.
In Development
FUNDED PROJECTS

EQUITY
$ 285000
Discovering Novel Autophagy Activators - Korolchuk Lab

EQUITY
$ 91300
ARTAN Bio - Mutation-Specific Codon Suppression for Aging and Longevity
FUNDING IRL
SCIENCE ONCHAIN
29
Projects
Funded
$6M+
Funding
Deployed
$26M
Projects
FDV
15
Target
Discovery
Projects
11
Drug
Discovery
Projects
3
Preclinical
Drug Dev
Projects
0
Clinical
Drug Dev
Projects
9
IPTs
Generated
3
Companies
Founded
FUNDING IRL
SCIENCE – ONCHAIN
29
Projects
Funded
$6M+
Funding
Deployed
$26M
Projects
FDV
15
Target
Discovery
Projects
11
Drug
Discovery
Projects
3
Preclinical
Drug Dev
Projects
0
Clinical
Drug Dev
Projects
9
IPTs
Generated
3
Companies
Founded
OUR VISIONARY PARTNERS
























OUR VISIONARY PARTNERS





